<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815174</url>
  </required_header>
  <id_info>
    <org_study_id>ALIMA01</org_study_id>
    <nct_id>NCT04815174</nct_id>
  </id_info>
  <brief_title>Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease</brief_title>
  <acronym>EVISTA</acronym>
  <official_title>Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for International Medical Action</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alliance for International Medical Action</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study highlighted the possibility, even in epidemic settings, of providing advanced&#xD;
      supportive care for patients with VMEs. Indeed, while the prospect of offering any invasive&#xD;
      medical care was widely discussed in 2014 in West Africa with the aim of limiting the&#xD;
      exposure of caregivers, the epidemic of 2018-2019 has on the contrary seen the development of&#xD;
      a number of medical care strategies, in parallel with the deployment of specific treatments.&#xD;
      This study aims to describe a cohort of patients receiving this upgraded supportive care&#xD;
      during the tenth epidemic in the DRC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Through the end of the hospitalization, with an average of 11 days</time_frame>
    <description>Any type mortality during hospitalization</description>
  </primary_outcome>
  <enrollment type="Actual">711</enrollment>
  <condition>Ebola Virus Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with positive RT-PCR admitted in ETC's during the inclusion period were&#xD;
        included in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory confirmed Ebola Virus Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BENI ETC</name>
      <address>
        <city>Beni</city>
        <state>Nord Kivu</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

